MS prescribing depends on balancing benefit against hard-to-assess risk. At the recent World Congress of Neurology in Vienna, two experts in MS debated whether physicians rate the risk of disabling MS less than the risk of effective treatment. The debate centered on how clinicians and patients perceive risk and how decision-making must be done collaboratively.

Laquinimod appears to reduce brain MRI findings of inflammatory destruction in relapsing-remitting multiple sclerosis

A new technique has identified changes in gray matter-related proteins in CSF that distinguished first-attack CIS from established relapsing-remitting MS and from controls